Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
Scottish Medicines Consortium
Record ID 32018000967
English
Authors' objectives:
To assess the clinical and cost effectiveness.
Details
Project Status:
Completed
URL for project:
https://www.scottishmedicines.org.uk/medicines-advice/secukinumab-cosentyx-full-smc2308/
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/secukinumab-cosentyx-full-smc2308/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Spondylarthritis
- Spondylitis, Ankylosing
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.